Par Pharmaceutical, Inc filed its notice of appeal for the distribution of injunction bonds in generic Megace ES patent suit

October 12, 2016. TWi Pharmaceuticals, Inc. (“TWi”)  (Stock Ticker: 4180.TT) today received a notice that Par filed its notice of appeal on October 11, 2016 (US time) to the United States Court of Appeals for the Federal Circuit from the order granting TWi's motion to distribute injunction bonds dated on September 27, 2016 (US time).
TWi will be prepared for the process accordingly.

About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high-entry-barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer unparalleled market opportunities in the United States.

Angela Luan
Investor Relations
Email: angela.luan@twipharma.com